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Background: There remain major uncertainties regarding disease activity within the retained 
native aortic valve as well as bioprosthetic valve durability following transcatheter aortic valve 
implantation (TAVI). We aimed to assess native aortic valve disease activity and bioprosthetic 
valve durability in patients with TAVI in comparison to subjects with bioprosthetic surgical 
aortic valve replacement (SAVR). 
Methods: In a multicenter cross-sectional observational cohort study, patients with TAVI or 
bioprosthetic SAVR underwent baseline echocardiography, CT angiography and 18F-sodium 
fluoride (18F-NaF) positron emission tomography (PET).  Participants (n=47) were imaged once 
with 18F-NaF PET/CT either at one-month (n=9, 19%), 2 years (n=22, 47%) or 5 years (16, 34%) 
after valve implantation. Subsequently patients underwent serial echocardiography to assess for 
changes in valve hemodynamic performance (change in peak aortic velocity) and evidence of 
structural valve dysfunction. Comparisons were made to matched patients with bioprosthetic 
SAVR (n=51) who had undergone the same imaging protocol. 
Results: In patients with TAVI, native aortic valves demonstrated 18F-NaF uptake around the 
outside of the bioprostheses that showed a modest correlation with the time from TAVI (r=0.36, 
p=0.023). 18F-NaF uptake in the bioprosthetic leaflets was comparable between the SAVR and 
TAVI groups (target-to-background ratio 1.3 [1.2-1.7] versus 1.3 [1.2-1.5] respectively, p=0.27). 
The frequencies of imaging evidence of bioprosthetic valve degeneration at baseline were similar 
on echocardiography (6% versus 8% respectively, p=0.78), CT (15% versus 14% respectively, 
p=0.87) and PET (15% versus 29% respectively, p=0.09). Baseline 18F-NaF uptake was 
associated with subsequent change in peak aortic velocity for both TAVI (r=0.7, p<0.001) and 
SAVR (r=0.7, p<0.001). On multivariable analysis, 18F-NaF uptake was the only predictor of 
peak velocity progression (p<0.001).  
Conclusions: In patients with TAVI, native aortic valves demonstrate evidence of ongoing 
active disease. Across imaging modalities, TAVI degeneration is of similar magnitude to 
bioprosthetic SAVR suggesting comparable mid-term durability. 
Clinical Trial Registration: URL: https://www.clinicaltrials.gov/ Unique Identifier: 
NCT02304276 
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CT – Computed tomography 
HALT – Hypoattenuated leaflet thickening 
HU – Hounsfield units 
PET – Positron emission tomography 
ROI – Region of interest 
SAVR – Surgical aortic valve replacement 
SD – Standard deviation 
SUV – Standard uptake value 
SVD – Structural valve deterioration 
TAVI – Transcatheter aortic valve implantation 










Clinical Perspective  
 
What is new? 
• After transcatheter aortic valve implantation, native aortic valves demonstrate evidence 
of ongoing disease activity, suggesting that aortic stenosis is an active disease process 
that is independent of motion and mechanical injury.  
• 18F-NaF PET identifies subclinical bioprosthetic degeneration of transcatheter aortic 
valves, providing prediction of subsequent valvular dysfunction and highlighting patients 
at risk of valve failure. 
• Across three complementary and distinct imaging modalities, bioprosthetic degeneration 
of transcatheter aortic valves appears to be of similar magnitude to bioprosthetic SAVR 
suggesting comparable mid-term durability.  
 
What are the clinical implications? 
• 18F-NaF PET holds promise in detection of bioprosthetic aortic valve degeneration and 












Transcatheter aortic valve implantation (TAVI) has revolutionized intervention options in aortic 
valve stenosis (1-4). Although the term TAVI and transcatheter aortic valve replacement 
(TAVR) are widely used interchangeably, TAVR is a misnomer since the native aortic valve is 
not replaced but rather displaced and splinted against the wall of the aorta at the time of 
bioprosthetic valve insertion. As a consequence, the native aortic valve is rendered immobile. 
Previously, it has been suggested that the impact of repeated valve closure and trauma is 
fundamental to aortic stenosis (5). Therefore, patients with TAVI present a unique opportunity to 
investigate the pathophysiology of aortic stenosis in the absence of the ongoing cyclical 
mechanical trauma of valve closure. Is aortic stenosis simply a disease of ‘wear-and-tear’ or is it 
an active regulated pathobiological process that continues despite valve immobilization? 
TAVI is rapidly gaining popularity as a treatment option in younger low-risk populations 
(2-4). With its more widespread use, questions regarding valve durability become increasingly 
important (6). All bioprosthetic valves are susceptible to degeneration, driven by similar 
processes to native aortic valve stenosis. Indeed, active calcification appears to be the final 
common pathway of such degeneration leading to bioprosthetic valve stenosis, leaflet tears and 
valvular regurgitation (7,8). Whilst transcatheter bioprostheses are similar in structure to surgical 
valves, it has been suggested that the increased effective orifice area of TAVI will result in 
improved longevity. However, others have proposed that crimping of TAVI bioprostheses 
coupled with incomplete asymmetric frame expansion and suboptimal leaflet coaptation may 
lead to accelerated structural valve deterioration (SVD) (9). Whilst long term hemodynamic 









durability in patients with TAVI and those with bioprosthetic surgical aortic valve replacement 
(SAVR).  
We have demonstrated that 18F-sodium fluoride (18F-NaF) positron emission tomography 
(PET) provides a marker of calcification activity and vascular injury across a range of 
cardiovascular conditions (10-15). In native aortic valve stenosis, 18F-NaF uptake can assess 
valve calcification activity, providing important pathophysiological insights, a measure of 
disease severity and act as a predictor of subsequent disease progression and clinical events (10, 
11). In bioprosthetic SAVR, 18F-NaF PET uptake is an early and sensitive marker of leaflet 
degeneration, providing powerful prediction of subsequent valve dysfunction and valve failure 
(12). 
In the present study, we sought to investigate whether the retained native aortic valves in 
patients undergoing TAVI demonstrate evidence of ongoing disease progression. Additionally, 
since long-term durability of transcatheter aortic valves is yet to be established, we aimed to 
establish whether bioprosthetic valve durability or degeneration was appreciably different 
between patients with TAVI or SAVR at mid-term follow-up. 
 
Methods 
Study Design and Patient Population 
Patients with aortic stenosis who had undergone previous TAVI (1 month, 2 years or 5 years 
prior to study inclusion) using a balloon-expandable or self-expanding bioprosthesis were 
prospectively recruited into an observational cross-sectional cohort study at 3 high-volume TAVI 
centers between September 2016 and November 2019 (Edinburgh Heart Centre, Cedars Sinai 









were under routine clinical follow-up and did not have established clinical evidence of 
bioprosthetic valve degeneration (16). Each patient underwent clinical assessment, 
echocardiography, hybrid 18F-NaF PET and computed tomography (CT) angiography at baseline 
with annual repeat echocardiography thereafter (Figure 1). We excluded patients unable to give 
informed consent, with claustrophobia, allergy to iodinated contrast, liver failure, chronic kidney 
disease (with estimated glomerular filtration rate <30 mL/min/1.73 m2), Paget's disease, 
metastatic malignancy, or an inability to tolerate the supine position. Patients with TAVI were 
compared to patients with SAVR valves undergoing the same research protocol (including multi-
modality imaging protocols, image analysis assessments and follow up) (NCT02304276). 
Patients were recruited prospectively, matching the age of SAVR and TAVI valves (time from 
valve implantation for aortic stenosis to imaging) in the two groups. Baseline and follow up data 
from the SAVR cohort in isolation have been reported previously (12). The study 
(NCT02304276) was conducted in accordance with the Declaration of Helsinki and was 
approved by NHS Scotland Research Ethics Committee (14/SS/1049), the Administration of 
Radioactive Substances Advisory Committee and Institutional Review Boards at all sites. 
Recruitment was prematurely halted due to the onset of SARS-CoV-2 pandemic and the 
potential vulnerability of our target population. Additionally, we encountered difficulties in 
recruiting patients at 5 years following TAVI who were both alive and well enough to undergo 
study procedures. The data that support the findings of this study are available from the 
corresponding author upon reasonable request. 
Aortic Valve Imaging 
Echocardiography  









thereafter according to American Society of Echocardiography guidelines (17). Aortic valve 
Doppler measurements were routinely assessed from the apex, suprasternal notch and right 
sternal edge to measure the peak aortic jet velocity, the mean gradient and the effective orifice 
area of the bioprosthesis. Mean values were taken from 3 measurements when subjects were in 
sinus rhythm and from 5 measurements if in atrial fibrillation. Bioprosthetic valve regurgitation 
was graded as mild, moderate or severe according to guideline recommendations on the basis of 
visual appraisal of color Doppler images, measurement of pressure half-time (milliseconds) and 
assessment for aortic flow reversal in diastole (17). 
PET/CT Imaging  
All patients underwent 18F-NaF PET at baseline on hybrid PET/CT scanners (128-slice Biograph 
mCT, Siemens Medical Systems, Knoxville, USA or Discovery 690/710 GE Healthcare, 
Milwaukee, WI, USA) using harmonized imaging protocols, 60 min after intravenous 
administration of 125 MBq of 18F-NaF (18) obtained in 3-dimensional mode in a single 30-min 
bed position centered on the valve. Attenuation-correction CT was performed before acquisition 
of PET data. Finally, electrocardiogram-gated contrast-enhanced CT angiography was performed 
on the same scanner with prospective gating in end-expiration. Patients were given beta-blockers 
if resting heart rate was >65 beats/min and in the absence of clinical contraindications. After co-
registration with PET, the CT data served for anatomical reference and facilitated PET tracer 
uptake quantification (19). 
Imaging Analysis 
Computed Tomography 
Abnormalities on CT angiography were adjudicated using pre-specified criteria. Non-calcific 









attenuation [30 to 200 Hounsfield Units (HU)] leaflet thickening visualized in at least 2 planes 
typically thickest at its base and thinning to the tips in accordance with consensus guidelines 
(20,21). Pannus was defined as circumferential low-attenuation (non-calcific) material with 
radial thickness ≥2 mm and encroachment on to the valve cusps (12). Leaflet calcification was 
defined as calcium >500 HU localized to a valve cusp in at least 2 planes and classified 
according to size as spotty calcification if maximum diameter was <3 mm, or large calcification 
if maximum diameter was ≥3 mm (22). 
Positron Emission Tomography 
Reconstructed ECG-gated PET and contrast-enhanced CT images were reoriented, co-registered 
in orthogonal planes and cardiac motion corrected with automatic algorithm preserving counts 
from all cardiac phases (supplemental methods) (23-26). Using en face images of the 
bioprosthetic valves, the maximum standard uptake values (SUV) in the native aortic valve was 
measured between the perimeter of the TAVI bioprostheses and the aorta. Care was taken to 
avoid regions of activity originating from the TAVI leaflets and nearby coronary arteries. Tissue 
to background ratio (TBR) values were derived from maximum SUV values corrected for blood-
pool activity (mean SUV) measured in the right atrium (1-cm radius 9-mm high cylinder drawn 
on axial slices, at the level of the right coronary ostium). 
With respect to 18F-NaF uptake in the TAVI bioprosthetic valves, PET scans were 
adjudicated to be abnormal if discernible 18F-NaF uptake originating from the valve leaflets was 
observed on 3 orthogonal planes. We quantified 18F-NaF uptake according to a previously 
proposed methodology where a circular (area 1 cm2) region of interest (ROI) was drawn around 
the area of maximal uptake originating in the valve cusps (12,27). ROIs were carefully drawn to 









related to surrounding native aortic valve tissue. In subjects with no visible (exceeding blood-
pool activity) uptake in the valve leaflets, a 1-cm2 circular ROI was drawn in the center of the 
valve (10-12). Maximum SUV values were extracted from these ROIs and divided by the blood-
pool activity measured in the right atrium to calculate the TBR values as described above. A 
similar approach was taken to the analysis of SAVR valves (12).  
Clinical Follow up 
Patients were invited to return annually for 2 years for repeat clinical assessment and 
echocardiography to assess for evidence of deterioration in hemodynamic bioprosthetic 
performance. In particular, change in peak velocity through the valve, change in mean pressure 
gradient and change in the effective orifice area were recorded. Changes in the grade of aortic 
regurgitation were documented.  
Bioprosthetic valve deterioration was determined at baseline and after follow-up and was 
categorized as: stage 1 a morphological abnormality (detected on echocardiography or CT), 
including HALT, calcification or pannus, in the absence of hemodynamic changes; stage 2 either 
moderate valve obstruction, moderate regurgitation or both; stage 3 either severe valve 
obstruction or regurgitation (9, 16).  
Patients were followed up for clinical events with outcome information obtained from 
local and national healthcare record systems that integrate primary and secondary health care 
records. The primary clinical endpoint of the study was a composite of bioprosthetic valve 
failure or repeat TAVI. Categorization of these outcomes was performed blinded to the PET 
imaging or other study data. Outcome data were collected in September 2020. 
Ex Vivo Assessment 









imaging findings, we studied surgically explanted native and bioprosthetic aortic valves obtained 
from patients with dysfunctional degenerated TAVI in the Cardiovascular Tissue Registry at St. 
Paul’s Hospital. Ex vivo histological (hematoxylin and eosin; Movat’s pentachrome), 
immunohistochemistry (runx2 and osteopontin) and 18F-NaF autoradiography assessments (8) 
were made on these samples in accordance with the approval of the Research Ethics Board of 
Providence Health Care (supplemental methods). 
Statistical Analysis 
We assessed the distribution of data with the Shapiro-Wilk test. Continuous parametric variables 
were expressed as mean (SD) and compared using Student's t tests. Non-parametric data were 
presented as median [interquartile interval], compared using Mann-Whitney U test and log 
transformed to achieve normality prior to inclusion in regression models and correlation. Fisher's 
exact test or chi-squared test was used for analysis of categorical variables. We assessed 
correlations with the Pearson’s coefficient. Multivariable linear regression modeling was used to 
assess the change in echocardiographic measures of bioprosthesis performance, clinical 
characteristics, and 18F-NaF uptake. The multivariable model was constructed with annualised 
peak velocity change (m/sec) as the dependent variable and age, sex, time after aortic valve 
replacement, presence of HALT, valve TBR and baseline peak velocity and abnormalities on CT 
as independent variables, selected on the basis of clinically relevant and plausible mechanisms 
that may relate to valvular degeneration. Model residuals were checked against fitted values and 
distributions confirmed with quantile-quantile plots. To assess imaging evidence of bioprosthetic 
valve degeneration in TAVI or SAVR, we compared the echocardiography, CT and 18F-NaF 
PET findings in our TAVI population with matched data from a previous study which 









modality imaging protocols and image analyses (12). Receiver operating characteristic (ROC) 
analysis was performed to identify the optimum cut-off for TBR to identify patients at increased 
risk of structural valve degeneration using Youden J statistic. Statistical analysis was performed 
with SPSS version 24 (IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM 
Corp), R studio and R software version 4.01 (R Foundation for Statistical Computing, Vienna, 
Austria). We used R packages: dlpyr, ggplot2, magrittr, QuantPsyc, Forestplot, cutpointr and 




We recruited 47 patients with TAVI from 3 high volume centers (81±6 years old, 79% male) 
who were compared with 51 patients with SAVR from the same institutions (Table 1). Similar to 
the SAVR cohort, patients with TAVI were imaged once with 18F-NaF PET/CT at either one 
month (n=9, 19%), 2 years (n=22, 47%) or 5 years (16, 34%) after valve implantation. Twenty-
five (53%) subjects were implanted with a balloon expanded bioprosthesis and 22 (47%) 
received a self-expanding valve.  
Calcification Activity in Native Aortic Valve Tissue 
Ex Vivo Validation 
In five patients with TAVI for severe aortic stenosis, explanted TAVI valves and associated 
aortic roots were obtained 945 (range 3-2044) days after implantation (Tables I and II in the 
supplement). Calcified native aortic valve tissue was present around the perimeter of the TAVI 









activity with increased staining for both osteopontin and Runx-2 (Figure 2, Figures I and II in the 
supplement).  
18F-Sodium Fluoride Positron Emission Tomography 
On contrast CT angiography at baseline, residual calcification from the native aortic valve was 
seen around the perimeter of the TAVI bioprosthesis in all cases. All subjects demonstrated 18F-
NaF uptake surrounding the TAVI bioprostheses that originated from the native aortic valve 
tissue (TBR range 1.6-5.8; Figure 2). Native valve 18F-NaF uptake was highest in patients 
imaged 5 years after TAVI (TBR 3.3 [2.6-3.9] versus 2.2 [1.9-2.5] in those imaged one month 
after TAVI, p=0.023; Figure 2). Overall native valve uptake showed a modest positive 
correlation with the time from TAVI (r=0.36, p=0.023).  
Assessments of Bioprosthetic Valve Degeneration 
Ex Vivo Validation 
In four explanted TAVI valves with evidence of valve leaflet degeneration, increased 18F-NaF 
uptake was seen on autoradiography, with co-localization of this signal to regions of calcification 
within the TAVI valve leaflets as observable on hematoxylin and eosin and Movat's pentachrome 
staining (Figure 3).  
Baseline Echocardiography and Computed Tomography 
On echocardiography during their baseline research visit, valve function was normal in all but 3 
patients. These 3 patients had 5-year-old TAVI valves and demonstrated increased transvalvular 
gradients. This had not been appreciated on previous clinical echocardiograms or clinical follow 
up. No patient had clinically significant valvular regurgitation. Leaflet morphology was 









CT scans had image quality suitable for leaflet assessments in 87% of patients. Only one patient 
had evidence of TAVI leaflet calcification on CT, demonstrating spotty calcification that was 
just discernible from the valve struts (Figure 3). Pannus formation was not observed in any of 
our patients. HALT was found in 6 (13%) patients, 5 of whom were imaged 5 years after TAVI 
and one patient imaged 1 month after implantation. Four of these patients demonstrated minimal 
(<25%) leaflet involvement, while 2 patients had pronounced HALT (exceeding 50% of the 
leaflets) causing restricted single leaflet motion on 4-dimensional CT. One patient with HALT 
had evidence of hemodynamic valve deterioration on echocardiography (mean pressure gradient 
24 mmHg). 
Overall, 8 patients had imaging evidence of bioprosthetic TAVI valve degeneration on 
echocardiography or CT. Seven of these patients were in the cohort of patients imaged 5 years 
following TAVI, with no differences in their baseline clinical characteristics compared to 
patients with similar aged TAVI valves but normal imaging (Table III in the supplement).  
Baseline 18F-Sodium Fluoride Positron Emission Tomography 
All patients had good image quality enabling assessment of 18F-NaF uptake in the bioprosthetic 
leaflets. There was no difference in 18F-NaF uptake in self-expandable versus balloon-
expandable TAVI bioprostheses (TBR: 1.3 [1.2-1.6] versus 1.3 [1.2-1.7], p=0.74). We detected 
18F-NaF uptake localized to the TAVI leaflets in 7 patients (15%), all imaged 5 years after TAVI 
(TBR range 1.6 to 5.9). Valve TBR values were nearly double those in patients without visually 
apparent leaflet uptake (2.3 [1.7-4.3] versus 1.3 [1.2-1.4], p<0.001). The 3 highest TBR values 
(range 3.0-5.9) were observed in the patients with evidence of hemodynamic structural valve 
deterioration on echocardiography (Stage 2 SVD; mean transprosthetic pressure gradients > 20 









degeneration on CT (Stage 1 SVD) compared to valves with normal echocardiographic and CT 
appearances (Figure 2). One patient had evidence of increased 18F-NaF leaflet uptake in the 
absence of any changes on CT or echocardiography. Of 6 patients presenting with HALT, 4 
showed increased 18F-NaF TAVI leaflet uptake (Figure 3 and Figure III in the supplement). 
Disease Progression and Clinical Outcomes 
Patients with TAVI underwent repeat echocardiographic evaluation at 15 [12-17] months to 
assess for evidence of progressive valve dysfunction. A strong correlation was observed between 
baseline 18F-NaF TBR values in the TAVI leaflets and the subsequent annualized change in 
bioprosthetic valve peak velocity on echocardiography (r=0.70, p<0.001; Figure 4). Similar 
correlations were observed between 18F-NaF leaflet uptake and the change in the mean pressure 
gradient (r=0.55, p=0.01) and the change in the effective orifice area (r=-0.71, p=0.007). On 
univariable analysis, the only predictors of the annualized change in peak velocity were valve 
age (p=0.035), abnormal CT findings (p=0.006) and 18F-NaF leaflet uptake (p<0.001; Table 2). 
On multivariable analysis incorporating age, sex, duration of valve implantation, baseline peak 
prosthetic valve velocity and abnormal CT findings, 18F-NaF uptake was the only predictor of 
the annualized change in peak velocity (p<0.001; Table 3).  
Four patients developed clinical criteria for hemodynamic SVD during the follow up 
period, with each developing bioprosthetic valve stenosis (mean pressure gradient 27 [24-31] 
mmHg and peak velocity 3.6 [3.4-4.1] m/s). Three patients had increased 18F-NaF TAVI leaflet 
uptake at baseline. In the single patient without increased 18F-NaF uptake at baseline, the 
increased mean pressure gradient normalized after 3 months of anti-coagulation therapy and in 
retrospect was attributed to valve thrombosis rather than established irreversible structural valve 









bioprosthesis failure 18 months after baseline PET and underwent a successful TAVI-in-TAVI. 
Based on the Youden’s index, the optimal cut-off TBR value to identify patients at increased risk 
of structural valve degeneration was 1.59. In our study, the 1.59 TBR threshold had a sensitivity 
of 86%, specificity of 89%, positive predictive value of 86%, negative predictive value of 97% 
and accuracy of 89% for prediction of hemodynamic valve degeneration. 
Comparison to Patients with Age-matched SAVR Valves 
Fifty-one patients with SAVR who underwent the same research imaging protocol were 
compared to the 47 patients with TAVI. The latter were older (82 [76-86] versus 72 [70-77] 
years, p<0.001) and had more co-morbidity than patients with SAVR. The time from valve 
replacement to imaging was similar (24 [24-60] vs 24 [24-60] months, p=0.91) as were the 
number of SAVR and TAVI patients imaged 1 month, 2 years and 5 years after valve 
replacement (Table 1). Patients with TAVI had lower peak aortic jet velocity (2.4 [2.0-2.7] vs 2.7 
[2.4-3.0] m/s, p=0.03) and larger effective orifice area (1.5 [1.3-1.8] vs 1.1 [1.0-1.5] cm2, p=0.02, 
Table 1) than patients with SAVR.  
Evidence of bioprosthetic degeneration was similar in TAVI and SAVR groups on 
echocardiography (6% vs 8% respectively, p=0.78) and CT (15% vs 14% respectively, p=0.87; 
Figure 5). While the overall prevalence of patients with increased leaflet 18F-NaF uptake 
appeared to be nearly double in patients with SAVR (29% versus 15% in those with TAVI), this 
did not reach statistical significance (p=0.09) and in those studied at 5 years, there was no 
difference in the proportion of patients demonstrating bioprosthetic uptake (40% SAVR vs 44% 
TAVI patients, p=0.79). Overall 18F-NaF uptake was similar in both TAVI and SAVR valves 











In patients with TAVI, we have demonstrated that 18F-NaF uptake within the native aortic valve 
is higher with longer duration of implantation suggesting disease activity continues despite 
immobilization of the valve leaflet. This was further supported by our histological finding of 
continued activation of pro-calcific markers in explanted native valves after TAVI. We have 
further shown using 3 complementary and distinct imaging modalities that the prevalence of 
valve degeneration within TAVI bioprostheses is similar to that of bioprosthetic SAVR valves 
for up to 7 years after valve replacement. Finally, we have confirmed that 18F-NaF PET of the 
bioprosthetic valve provides a powerful independent predictor of subsequent hemodynamic 
bioprosthetic valve degeneration that is applicable to both TAVI and SAVR and outperforms all 
other traditional risk factors. We conclude that aortic stenosis is an active regulated disease 
process rather than solely the result of simple wear and tear of the valve, and that TAVI appears 
to have similar durability to SAVR with comparable modest rates of mid-term bioprosthetic 
valve degeneration. 
 We have previously established 18F-NaF PET as a tool for the in vivo assessment of 
calcification activity across multiple different cardiovascular disease states (10-15). In patients 
with aortic stenosis, valvular 18F-NaF uptake provides an assessment of disease activity and 
prediction of subsequent disease progression and clinical events (10,11). We have here 
demonstrated that 18F-NaF uptake continues to occur in the retained native aortic valve of all 
patients with TAVI. We had hypothesized that 18F-NaF uptake might have transiently increased 
early following TAVI when native valve calcium has been disrupted, thereby increasing the 
available surface area for 18F-NaF binding. Thereafter, 18F-NaF uptake would be anticipated to 









we observed the opposite. Native aortic valve18F-NaF uptake and calcification activity was 
higher with longer duration of implantation. We observed a modest correlation between native 
valve uptake and the time from TAVI. This finding was supported by our ex vivo data that 
demonstrated histological evidence of ongoing calcification activity in native aortic valve tissue 
many years following TAVI. These observations are consistent with the hypothesis that once 
established, calcification activity in the native aortic valve continues to accelerate in an ongoing 
pathobiological process with continuing mineralization (the propagation phase) that is not halted 
even following TAVI (28). Indeed, the fact that it continues several years after TAVI, when 
mechanical stresses are no longer being exerted on the valve leaflets, confirms that aortic 
stenosis is an active regulated disease process and not simply the result of valve wear and tear. 
Therapies focused on slowing this cycle of calcification are required if we are going to develop 
the medical treatments for aortic stenosis that are so urgently needed. Medications interfering 
with tissue calcification and ectopic bone formation (alendronate and denosumab) have recently 
been tested in this context but unfortunately were unable to alter aortic valve calcification or 
disease progression (5, 29, 30). 
In patients with bioprosthetic SAVR, 18F-NaF uptake provides a marker of bioprosthetic 
valve degeneration and a powerful predictor of subsequent valve dysfunction (12). Our current 
study extends these findings to patients with TAVI, demonstrating that increased 18F-NaF uptake 
in the bioprosthetic valve leaflets provides an early indication of valve degeneration and a more 
powerful predictor of subsequent valve dysfunction than valve age, cardiovascular co-
morbidities and imaging assessments provided by echocardiography and computed tomography. 
Interestingly, the association between baseline bioprosthetic leaflet 18F-NaF uptake and 









(r=0.7, p<0.001) to that previously reported for bioprosthetic SAVR valves (r=0.7, p<0.001). 
Combined with the existing bioprosthetic SAVR data, this positions 18F-NaF PET as a highly 
promising marker of early bioprosthetic valve degeneration that might provide important value in 
the prediction of bioprosthesis failure, particularly as other imaging modalities such as 
echocardiography and CT are currently limited in this regard. Future trials are now required to 
assess whether this molecular imaging technique can aid clinical decision making and risk 
stratify patients with bioprosthetic valves. Based on the findings of this study, one potential 
strategy would be to perform a 5-year 18F-NaF PET scan after TAVI as a screening tool for 
identifying those at increased risk of rapid deterioration. This might help the planning of repeat 
intervention and differentiate patients who require close monitoring from those with no evidence 
of even early valve degeneration who can be assessed much less frequently.  
 Given the powerful prediction of valve dysfunction provided by 18F-NaF in both 
bioprosthetic SAVR and TAVI valves, our dataset provides a unique opportunity to compare 
early valve degeneration in age-matched bioprosthetic SAVR and TAVI valves, thereby helping 
address one of the most important current questions in heart valve disease. Are TAVI valves 
likely to last as long as surgical bioprostheses? In the present study, there were no differences in 
the proportion of patients with TAVI or SAVR bioprostheses who had echocardiographic or CT 
evidence of valve degeneration for up to 7 years after replacement. Very similar rates of 
increased 18F-NaF uptake were observed in patients with SAVR and TAVI valves implanted 5 
years previously (40 versus 44 %) despite patients with TAVI having a much higher burden of 
cardiovascular co-morbidities. Taken together, our data suggest that imaging assessments of 
valve degeneration are similar between these two types of valve, supporting similar mid-term 









would help assuage one of the main lingering concerns about performing TAVI as the first line 
valve replacement method in patients with aortic stenosis.  
Our study has several strengths and weaknesses. We have employed a state-of-the-art 
multi-modality imaging study design and employed the same protocols to image patients with 
age matched SAVR and TAVI valves thereby providing a unique opportunity to compare 
imaging findings in these 2 valve types. Moreover, we provide longitudinal data confirming the 
predictive value of 18F-NaF PET in both SAVR and TAVI valves. Whilst relatively large for a 
complex molecular imaging study, our overall sample size is modest (47 TAVI and 51 SAVR 
valves). Our observations therefore require confirmation in larger data sets with longer follow-
up. Patients with bioprosthetic SAVR and TAVI were not matched for age nor co-morbidities 
however, given the different patient populations who currently received these two treatments, 
this is inevitable, and our results would suggest that these co-morbidities do not greatly influence 
valve degeneration nor durability. Given the cross-sectional nature of our study, we acknowledge 
the potential for survivor bias. This could be addressed in future longitudinal cohort studies to 
ensure prospective capture of all cases of valvular degeneration. Due to the outbreak of SARS-
CoV-2 pandemic, we discontinued further recruitment before reaching our pre-defined number 
of study participants and therefore further studies are needed to confirm our findings. Finally, in 
our study, we focused on bioprosthetic valves, and our findings should not be extrapolated to 
mechanical aortic valve prostheses which have better durability than both forms of bioprosthetic 
valve.  
 In conclusion, we have demonstrated that native aortic valves after TAVI demonstrate 
evidence of ongoing disease activity, suggesting that aortic stenosis is an active disease process 









imaging modalities, TAVI degeneration appears to be of similar magnitude to bioprosthetic 
SAVR suggesting comparable mid-term durability. 18F-NaF PET appears to be a consistent 
method of detecting early bioprosthetic valve degeneration and predicting subsequent 
dysfunction for both TAVI and SAVR. 
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Table 1. Comparison of patients following transcatheter aortic valve implantation versus patients following 
surgical aortic valve replacement.  
 
 Patients with transcatheter 
bioprosthetic valves 
n=47 




Age (years) 82 [76-86] 72 [70-77] <0.001 
Men 29 (62%) 29 (57%) 0.63 
Body-mass index (kg/m2) 24 [20-26] 27 [24-32] <0.001 
Systolic blood pressure (mmHg) 132 [120-146] 156 [142-165] <0.001 
Diastolic blood pressure (mmHg) 68 [60-73] 80 [73-87] <0.001 
Heart rate 63 [59-74] 70 (63-82) 0.03 
Bioprosthesis age 
Time since valve replacement (months) 24 [24-60] 24 [24-60] 0.91 
5 years post valve replacement 16 (34%) 20 (39%) 0.65 
2 years post valve replacement 22 (47%) 22 (43%) 0.68 
1 month post valve replacement 9 (19%) 9 (18%) 0.79 
Comorbidities 
Hypertension 38 (80%) 38 (75%) 0.45 
Hyperlipidemia 24 (51%) 39 (76%) 0.01 
Diabetes 15 (31%) 3 (6%) 0.02 
Smoking 28 (60%) 25 (49%) 0.31 
Coronary Artery Disease 24 (51%) 18 (35%) 0.12 
coronary artery bypass grafts 17 (31%) 14 (27%) 0.35 
Medication 
Aspirin 27 (57%) 37 (73%) 0.12 
P2Y12 antagonist 8 (17%) 7 (14%) 0.65 
Warfarin 7 (14%) 4 (8%) 0.27 
Direct Oral Anticoagulation 1 (2%) 1 (2%) 0.85 
ACE inhibitor/angiotensin receptor blocker 30 (63%) 28 (55%) 0.37 
Beta blocker 28 (60%) 24 (47%) 0.21 
Statin 35 (74%) 35 (68%) 0.52 
Electrocardiogram 
Sinus rhythm 27 (57%) 47 (92%) <0.001 
Paced rhythm 9 (20%) 0 <0.001 
Atrial Fibrillation 7 (14%) 2 (4%) 0.06 
Left ventricular hypertrophy 5 (11%) 20 (39%) 0.01 
Left ventricular hypertrophy – with strain 3 (7%) 12 (24%) 0.02 
Echocardiography 
Evidence of valve degeneration 3 (6%) 4 (8%) 0.78 
Evidence of valve degeneration in 5-year-old valves 3 (19%) 4 (20%) 0.78 
Reduced LV ejection fraction 9 (19%) 8 (16%) 0.65 
Vmax (m/s) 2.4 [2.0-2.7] 2.7 [2.4-3.0] 0.03 
Mean valve gradient (mm Hg) 12 [9-14] 15 [12-19] 0.18 
Effective orifice area (cm2) 1.5 [1.3-1.8] 1.1 [1.0-1.5] 0.02 
Computed Tomography 
CT evidence of valve degeneration  7 (15%) 7 (14%) 0.87 
CT evidence of valve degeneration in 5-year-old 
valves 









Spotty calcification 1 (2%) 2 (4%) 0.61 
Pannus 0 2 (4%) 0.07 
Hypoattenuated leaflet thickening 6 (13%) 4 (8%) 0.42 
18F-Sodium Fluoride Positron Emission Tomography 
Increased leaflet 18F-NaF 7 (15%) 15 (29%) 0.09 
Increased leaflet 18F-NaF in 5-year-old valves 7 (44%) 8 (40%) 0.79 
Target to background ratio 1.3 [1.2-1.7] 1.3 [1.2-1.5] 0.27 
Number (%); median [interquartile range]  










Table 2. Factors associated with future deterioration in TAVI function (annualized change in 
peak velocity after 2 years): univariable analysis. 
 










Sex 0.106 (-0.491 to 0.704) 0.298 0.083 0.72 
Age -0.006 (-0.040 to 0.027) 0.013 -0.086 0.70 
Body-mass Index -0.016 (-0.064 to 0.031) 0.023 -0.169 0.47 
Valve Age 0.139 (0.011 to 0.268) 0.064 0.431 0.035 
Valve Type -0.021 (-0.050 to 0.010) 0.015 -0.085 0.54 
Systolic blood pressure -0.005 (-0.021 to 0.011) 0.013 -0.153 0.50 
Hypertension 0.028 (-1.318 to 1.373) 0.6429 0.010 0.96 
Diabetes 0.104 (-0.473 to 0.681) 0.276 0.086 0.71 
Dyslipidemia 0.255 (-0.713 to 1.224) 0.463 0.126 0.59 
Smoking -0.865 (-2.096 to 0.366) 0.479 -0.628 0.13 
Baseline Peak Velocity -0.2417 (-0.850 to 0.367) 0.294 -0.173 0.42 
Hypoattenuated leaflet thickening 
on CT 
0.4495 (-0.346 to 1.245) 
 
0.383 0.242 0.25 
Abnormal CT findings 0.889 (0.277 to 1.501) 0.295 0.540 0.006 
Native valve TBR 0.032 (-0.218 to 0.282) 0.120 0.058 0.79 
TAVI TBR 0.509 (0.348 to 0.669) 0.078 0.813 <0.001 











Table 3. Factors associated with future deterioration in TAVI function (annualized change in 
peak velocity after 2 years): multivariable analysis.  
 
MULTIVARIABLE ANALYSIS: 
PREDICTORS OF PROGRESSION IN PEAK VELOCITY 
SUMMARY:                              R = 0·760                                              R Square 0.580                p = 0.002 






Age -0.013 (-0.039 to 0.012) 0.012 -0.176 0.287 
Sex 0.109 (-0.303 to 0.520) 0.193 0.090 0.447 
Valve Age -0.029 (-0.171 to 0.113) 0.066 -0.088 0.663 
Baseline Peak Velocity -0.09 (-0.552 to 0.366) 0.214 -0.070 0.670 
Abnormal CT findings 0.565 0.445 0.330 0.225 
TAVI TBR 0.476 (0.244 to 0.727) 0.114 0.628 <0.001 
TAVI: transcatheter aortic valve implantation; TBR: target to background ratio. 











Figure 1. CONSORT flow diagram of study recruitment, allocation (assessments), follow-
up and analysis. 
 
Figure 2. Baseline assessment with 18F-sodium fluoride activity in native aortic valve tissue 
following transcatheter aortic valve replacement.  
A: Hybrid 18F-sodium fluoride positron emission tomography and computed tomography (18F-
NaF PET/CT) en face and long axis images of native aortic valve tissue uptake. We observed 
intense tracer activity originating from the native valve tissue around the perimeter of the 
bioprosthesis in all patients with transcatheter aortic valve replacement (TAVI). B: Native aortic 
valve 18F-NaF uptake in patients with TAVI was higher with longer duration since bioprosthesis 
implantation suggesting increased calcification activity following intervention. C: 
Representative macroscopic images of explanted TAVI valves (green arrow) surrounded by 
native aortic valve (red arrow) jailed between the bioprostheses and the aortic root (blue arrow): 
ventricular aspect (left), aortic aspect (middle) and view of the root with native valve tissue cut 
and opened out along its perimeter (right). D: Histology (Movat's pentachrome staining) and 
immunohistochemistry of native aortic valves showing morphology, high expression of Runx2 
and osteopontin in the native aortic valves explanted a month, 32 and 53-months post-TAVI. 
 
Figure 3. 18F-Sodium fluoride identifies early TAVI bioprosthetic valve degeneration.  
A: Top row: a 76-year-old female with hemodynamic valve deterioration on echocardiography 









tomography angiography revealed spotty calcification on the bioprosthetic leaflets. On 18F-
sodium fluoride positron emission tomography (18F-NaF PET), we detected very high uptake in 
the leaflets (target-to-background [TBR] = 5.9). The patient developed bioprosthesis failure 18 
months after baseline PET and underwent a successful TAVI-in-TAVI. Second row: an 88-year-
old male with hemodynamic valve deterioration on echocardiography imaged 5 years after 
TAVI. Computed tomography angiography revealed hypoattenuated leaflet thickening. On 18F-
NaF PET we detected very high uptake in the leaflets (TBR = 3.8). B: There was a stepwise 
increase in TAVI 18F-NaF uptake according to the presence and severity of valve dysfunction. 
18F-NaF uptake was highest in patients with hemodynamic dysfunction, and more pronounced in 
those with structural valve deterioration (SVD) than normal TAVI valves. C: Histological and 
autoradiography validation of 18F-NaF avidity in a Edwards CE TAVI valve explanted after 86 
months: Movat's pentachrome and hematoxylin and eosin staining, demonstrate that leaflet 
calcification corresponds closely with 18F-NaF binding on autoradiography.  
 
Figure 4. Baseline 18F-sodium Fluoride Uptake Predicts Subsequent Deterioration in TAVI 
Function.  
A: Case example of an 84-year-old patient imaged 5 years following transcatheter aortic valve 
replacement (TAVI). We detected TAVI 18F-sodium fluoride (18F-NaF) leaflet uptake in the 
absence of abnormalities on echocardiography (mean pressure gradient 11 mmHg) and computed 
tomography (CT). At follow up, the patient developed moderate bioprosthesis stenosis with 
mean pressure gradient of 23 mmHg. B: A strong correlation was observed between baseline 
18F-NaF uptake in the TAVI valves (TBR) and subsequent progression in bioprosthetic valve 









intervals) from a multivariable linear regression analysis predicting change in TAVI valve 
function (annualized change in peak velocity) during follow-up. When examining all relevant 
baseline characteristics, 18F-NaF uptake was the only independent predictor of hemodynamic 
TAVI deterioration. 
Figure 5. Comparison of imaging findings and valve deterioration in TAVI versus 
bioprosthetic SAVR.  
We compared echocardiographic, computed tomography (CT) and 18F-sodium fluoride (18F-NaF) 
findings in 47 patients with transcatheter aortic valve replacement (TAVI) with 51 patients with 
surgical aortic valve replacement (SAVR) who underwent the same research imaging protocol. 
We observed 18F-NaF uptake on the peripheral of all TAVI valves and none of the SAVR valves. 
While patients with TAVI showed lower peak velocity (2.4 [2.0-2.7] vs 2.7 [2.4-3.0] m/s, 
p=0.03) and larger effective orifice area (1.5 [1.3-1.8] vs 1.1 [1.0-1.5] cm2, p=0.02) than patients 
with SAVR, we detected baseline echocardiographic (6 vs 8% p=0.78) and CT abnormalities (15 
vs 14% p=0.87) suggestive of bioprosthetic degeneration in a similar proportion of patients with 
either TAVI or SAVR. The overall prevalence of patients with increased leaflet 18F-NaF uptake 
was nearly double in patients with SAVR compared to those with TAVI (29% and 15%, p=0.09). 
In both patients with SAVR or TAVI, baseline 18F-NaF leaflet uptake was predictive of the 
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